An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

AstraZeneca (Nasdaq: AZN) Roche (OTCQX: RHHBY) September 17, 2024 - Investorideas , a go-to investing platform, releases the first of a two-part series looking at news and developments for the ...

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

Seal Security, a leading provider of open source vulnerability and patch management solutions, has been authorized by the Common Vulnerabilities and Exposures (CVE®) Program as a CVE Numbering ...

Data from the study showed that the drug reduced the risk of disease progression or death by nearly half when compared to Keytruda. This data conforms with the initial results reported by SMMT in ...

Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer. In the first line of treatment, Rybrevant ...

Pharmac also announced that Opdivo, which treats kidney cancer, will be funded from our investment from 1 November. “It is expected that 600 eligible people will have access to Keytruda and Opdivo in ...